Rimanti, Anita
 Distribuzione geografica
Continente #
NA - Nord America 249
EU - Europa 116
AS - Asia 85
SA - Sud America 23
AF - Africa 2
Totale 475
Nazione #
US - Stati Uniti d'America 244
CN - Cina 34
IE - Irlanda 31
SG - Singapore 25
SE - Svezia 22
GB - Regno Unito 21
BR - Brasile 18
HK - Hong Kong 15
DE - Germania 11
RU - Federazione Russa 7
IT - Italia 6
VN - Vietnam 6
UA - Ucraina 4
CA - Canada 3
PL - Polonia 3
BG - Bulgaria 2
FI - Finlandia 2
FR - Francia 2
MX - Messico 2
PY - Paraguay 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
CH - Svizzera 1
CO - Colombia 1
EC - Ecuador 1
ES - Italia 1
IN - India 1
JP - Giappone 1
KR - Corea 1
LT - Lituania 1
NL - Olanda 1
RO - Romania 1
TR - Turchia 1
Totale 475
Città #
Dublin 31
Ashburn 29
Santa Clara 26
Fairfield 24
Chandler 20
Ann Arbor 17
Singapore 17
Hong Kong 15
Woodbridge 12
Houston 11
Seattle 11
Southend 10
Nyköping 8
Beijing 7
Cambridge 7
London 7
Jacksonville 6
Dearborn 5
New York 5
Wilmington 5
Ho Chi Minh City 4
Los Angeles 4
Modena 4
San Diego 3
Shanghai 3
São Paulo 3
Boardman 2
Bremen 2
Changsha 2
Chicago 2
Chiswick 2
Eugene 2
Hillsboro 2
Johannesburg 2
Moscow 2
Munich 2
Nanjing 2
Porto Alegre 2
Princeton 2
Sofia 2
Angelina 1
Bologna 1
Boston 1
Brooklyn 1
Buffalo 1
Capitão Poço 1
Capivari 1
Carapicuíba 1
Cleveland 1
Da Nang 1
Dallas 1
Dubai 1
Duque de Caxias 1
Elmhurst 1
Falkenstein 1
Fremont 1
Guarujá 1
Guayaquil 1
Hanoi 1
Hefei 1
Helsinki 1
Honolulu 1
Jersey City 1
João Pessoa 1
Kilburn 1
Kulgam 1
Linyi 1
Loma Plata 1
Mexico City 1
Milwaukee 1
Montreal 1
Nanchang 1
Norwalk 1
Nova Iguaçu 1
Nuremberg 1
Orem 1
Phoenix 1
Pinhais 1
Piranhas 1
Pittsburgh 1
Puyang Chengguanzhen 1
Querétaro 1
Salt Lake City 1
San Juan 1
Santa Maria 1
Seoul 1
Shenzhen 1
Sorocaba 1
Stockholm 1
Tampa 1
Tokyo 1
Toronto 1
Várzea Paulista 1
Warsaw 1
Winnetka 1
Wuhan 1
Zipaquirá 1
Totale 379
Nome #
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 251
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 227
Totale 478
Categoria #
all - tutte 1.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.749


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 4 2 6 4 8 2 7
2021/202233 1 0 1 3 1 4 1 0 3 6 10 3
2022/202374 5 11 3 5 8 4 1 1 34 0 0 2
2023/202427 1 3 3 0 4 2 3 5 0 1 2 3
2024/2025103 4 0 0 7 19 19 15 6 11 4 6 12
2025/2026106 17 6 19 27 29 8 0 0 0 0 0 0
Totale 478